Paysign Reports FY2024 Revenue of $58.38M and Acquires Gamma Innovation Assets

Paysign, Inc.

Full-year 2024 total revenues increased 23.5% to $58.38 million, with pharma patient affordability revenue up 214.5%.
Full-year 2024 net income was $3.82 million ($0.07 per diluted share), down from $6.46 million in 2023 due to prior year tax benefit.
Adjusted EBITDA rose 43.3% to $9.62 million, or $0.17 per diluted share, in 2024.
Acquired assets of Gamma Innovation LLC for cash and 2.5M restricted shares vesting over four years, plus up to 500K earn-out shares.
Appointed Michael Ngo, former Gamma managing member, as Chief Innovation Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.